1. Home
  2. IMRN vs KNRX Comparison

IMRN vs KNRX Comparison

Compare IMRN & KNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.19

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Logo KNOREX LTD. Class A Ordinary Shares

KNRX

KNOREX LTD. Class A Ordinary Shares

HOLD

Current Price

$0.32

Market Cap

10.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMRN
KNRX
Founded
1994
2009
Country
Australia
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
9.6M
10.9M
IPO Year
2016
2023

Fundamental Metrics

Financial Performance
Metric
IMRN
KNRX
Price
$1.19
$0.32
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.5M
4.8M
Earning Date
02-25-2026
06-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$0.30
52 Week High
$2.38
$3.45

Technical Indicators

Market Signals
Indicator
IMRN
KNRX
Relative Strength Index (RSI) 45.83 40.06
Support Level $1.01 $0.33
Resistance Level $1.24 $0.49
Average True Range (ATR) 0.15 0.03
MACD -0.03 -0.00
Stochastic Oscillator 13.91 12.79

Price Performance

Historical Comparison
IMRN
KNRX

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

About KNRX KNOREX LTD. Class A Ordinary Shares

Knorex Ltd is a B2B technology company providing programmatic advertising products and solutions to marketers to streamline and automate their advertising and marketing workflows. The company's product, Knorex XPOSM, is a self-service, enterprise-grade cloud platform with a suite of advertising management and execution (AMX) applications.

Share on Social Networks: